| Serial Number | 79409376 |
| Word Mark | MYTOCEL MSK |
| Filing Date | Thursday, September 19, 2024 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Saturday, January 18, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Indication of Colors claimed | The colors light blue, purple, and dark blue are claimed as a feature of the mark. |
| Goods and Services | Medical apparatus and instruments; medical devices for tissue regeneration. |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 14, 2024 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | REGENERA ACTIVA WORLDWIDE S.L. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | ES |
| Party Name | REMEDI S.à. r.l. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | LU |
| Event Date | Event Description |
| Thursday, November 14, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, November 15, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, November 15, 2024 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, December 18, 2024 | ASSIGNED TO EXAMINER |
| Saturday, December 21, 2024 | NON-FINAL ACTION WRITTEN |
| Sunday, December 22, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, January 18, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, January 18, 2025 | REFUSAL PROCESSED BY MPU |
| Sunday, February 9, 2025 | REFUSAL PROCESSED BY IB |
| Thursday, March 13, 2025 | CHANGE OF OWNER RECEIVED FROM IB |